Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|February 1, 2010
- Applied Clinical Trials-02-01-2010
- Volume 0
- Issue 0
Applied Clinical Trials Digital Edition - February 2010
REGULATORY : Avoiding Adverse Event Setbacks in Early Studies TRIAL DESIGN : Proposed Payment Models For the Phase I Volunteer European Pediatric Survey Unveils Research Challenges Also in this issue : FDA Commissioner Wraps Up Her First Year, EU Focuses on Inclusion of Elderly in Trials, Clinical Data Warehouses Stall in Real World, How Pediatric Networks Benefit Children
Advertisement
Articles in this issue
about 16 years ago
Applied Clinical Trials Digital Edition - October 2010over 16 years ago
Prepare Early for Adverse Eventsover 16 years ago
Paying the Phase I Volunteerover 16 years ago
When Great Ideas Meet the Real Worldover 16 years ago
Business and People Update February 2010over 16 years ago
Science and Research Top FDA Prioritiesover 16 years ago
EMEA Sees Benefits for Childrenover 16 years ago
Aging Under the Microscope in Europeover 16 years ago
How to Improve Children's Researchover 16 years ago
Cardiovascular Drug ActivityAdvertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
5